|1.||Skrzydlewski, Zdzisław: 5 articles (10/2005 - 08/2003)|
|2.||Skrzydlewski, Z: 5 articles (01/2005 - 03/2000)|
|3.||Mielicki, Wojciech P: 4 articles (10/2015 - 06/2008)|
|4.||Snarska, Jadwiga: 4 articles (03/2006 - 01/2003)|
|5.||Szajda, Sławomir Dariusz: 4 articles (10/2005 - 09/2004)|
|6.||Kozuszko, B: 4 articles (09/2001 - 03/2000)|
|7.||Zwierz, Krzysztof: 3 articles (03/2006 - 10/2005)|
|8.||Chabielska, Ewa: 3 articles (03/2006 - 06/2005)|
|9.||Darewicz, Barbara: 3 articles (10/2005 - 01/2005)|
|10.||Kudelski, Jacek: 3 articles (10/2005 - 01/2005)|
|1.||Venous Thrombosis (Deep-Vein Thrombosis)
06/01/1997 - "We conclude that, in this study, prothrombinase rather than tenase inhibition was more effective in reducing venous thrombosis and that these effects can be achieved without disruption of extravascular hemostasis."
06/01/1997 - "In order to investigate the respective roles of prothrombinase and intrinsic tenase (IXa/VIIIa) in venous thrombosis, we compared the anti-thrombotic efficacy of inhibitors of these two coagulation complexes. "
03/03/2015 - "To explore the functions of inflammatory cytokine, tissue factor (TF) and cancer procoagulant (CP) in non-tumor deep venous thrombosis (NT-DVT). "
11/01/1989 - "The two objectives of the study were to determine whether a procedure could be developed for measuring cancer procoagulant (CP) activity in human serum and if this procedure provided a method for distinguishing people with cancer from those without cancer. "
03/01/2012 - "We conclude that cancer procoagulant could potentially play a part in angiogenesis in cancer and vascular development during embryonic development."
01/01/2005 - "It was isolated from the rabbit's neoplasm type V2 Ca and then characterized and named as cancer procoagulant (CP). "
01/01/2003 - "The level of cancer procoagulant also increased in cancer tissues as well as in the serum. "
10/01/2000 - "[Expression of thrombogenic substances by neoplasms: TF and cancer procoagulant. "
07/01/2015 - "These disrupt FVIII activity predominantly by preventing the formation of the tenase complex, leading to a serious bleeding disorder. "
09/01/2005 - "The physiological relevance of the tenase complex is evident in hemophilia A or B patients who present with bleeding disorders. "
03/06/2015 - "Furthermore, in vitro and in vivo studies suggested that fractions of 6-12 kDa may be very promising compounds as putative selective intrinsic Xase inhibitors with antithrombotic action, but without the consequences of major bleeding and factor XII activation. "
04/01/2012 - "This study was aimed to investigate the pro coagulation effects of hemocoagulase atrix and its effective components (batroxobin and factor X activator) on plasma of normal subjects and patients with bleeding disorders and their mechanisms. "
11/01/2006 - "FVIII is an important cofactor in the tenase coagulation factor complex, lack of FVIII causes severe bleeding, whereas high FVIII levels seem to be associated with venous and arterial thromboembolism. "
09/01/2004 - "[Cancer procoagulant activity in serum and neoplastic tissue in cases of cervical and uterine carcinoma]."
01/15/1990 - "The activity of cancer procoagulant (CP) during the development of Guérin epithelioma was studied in the blood of Wistar rats. "
01/15/1990 - "Cancer procoagulant in serum of rats during development of experimental epithelioma."
09/24/1985 - "Cancer procoagulant, a proteolytic procoagulant enzyme, has been purified from rabbit V2 carcinoma extracts by two procedures. "
03/01/1981 - "Cancer procoagulant was purified from a rabbit V2 carcinoma. "
|5.||Colorectal Neoplasms (Colorectal Cancer)
01/01/2001 - "Examination results point to the possibility of using the evaluation of cancer procoagulant activity in monitoring the course of treatment of patients with oesophagal, gastric and colorectal cancer."
01/01/2001 - "Cancer procoagulant activity in the blood serum of patients with oesophagal, gastric and colorectal cancer was evaluated before and after the tumour removal. "
01/01/2001 - "Cancer procoagulant as a marker in monitoring the therapy in cases of oesophageal, stomach and colorectal cancer."
03/01/2000 - "[Diagnostic significance of cancer procoagulant activity in colorectal cancer]."
09/01/2001 - "The cancer procoagulant activity has been evaluated in homogenates of esophagal, stomach and colorectal cancer tissues and in the blood serum of patients with these neoplasms's. "
|1.||Thromboplastin (Tissue Factor)
|2.||Factor X (Stuart Factor)
|3.||Cysteine Proteases (Cysteine Protease)
|7.||Factor XII (Hageman Factor)
|1.||Drug Therapy (Chemotherapy)